A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial
-
Published:2023-05
Issue:3
Volume:18
Page:369-381
-
ISSN:1776-2596
-
Container-title:Targeted Oncology
-
language:en
-
Short-container-title:Targ Oncol
Author:
Izawa Naoki, Masuishi Toshiki, Takahashi Naoki, Shoji Hirokazu, Yamamoto Yoshiyuki, Matsumoto Toshihiko, Sugiyama Keiji, Kajiwara Takeshi, Kawakami Kentaro, Aomatsu Naoki, Kondoh Chihiro, Kawakami Hisato, Takegawa Naoki, Esaki Taito, Shimokawa Mototsugu, Nishio Kazuto, Narita Yukiya, Hara Hiroki, Sunakawa Yu, Boku Narikazu, Moriwaki Toshikazu, Eguchi Nakajima TakakoORCID, Muro Kei
Funder
Taiho Pharmaceutical Merck KGaA
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference40 articles.
1. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Eng J Med. 2015;372:1909–19. 2. Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018;36:350–8. 3. Pfeiffer P, Yilmaz M, Möller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:412–20. 4. Tsukihara H, Nakagawa F, Sakamoto K, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 2015;33:2135–42. 5. Emura T, Nakagawa F, Fujioka A, et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med. 2004;13:249–55.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|